Skip to content

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

Menu

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

August 2022

ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

Portfolio News / By Karina Tin

August 11, 2022

RAPT Therapeutics Reports Second Quarter 2022 Financial Results

Portfolio News / By Karina Tin

August 11, 2022

Surrozen Reports Second Quarter 2022 Financial Results

Portfolio News / By Karina Tin

August 11, 2022

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results & Provides Business Update

Portfolio News / By Karina Tin

August 10, 2022

eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Portfolio News / By Karina Tin

August 9, 2022

eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

Portfolio News / By Karina Tin

August 8, 2022

Kallyope’s Newly Established Clinical Development Advisory Board Joined By Renowned Biopharma Leaders

Portfolio News / By Karina Tin

August 5, 2022

NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results

Portfolio News / By Karina Tin

August 4, 2022

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Portfolio News / By Karina Tin

August 3, 2022

Search for:

Recent Posts

Carmot Therapeutics Enters into Definitive Merger Agreement with Roche
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)
Escient Pharamceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist, In Atopic Dermatitis
RAPT Therapeutics Announces Publication of Phase 1A/1B Clinical Trial of Zelnecirnon (RPT193) To Treat Atopic Dermatitis In Allergy
Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes

Recent Comments

Archives

Categories

Portfolio News
TCG News

The Column Group

Copyright © 2022. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications

Scroll to Top